The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Subscribe To Our Newsletter & Stay Updated
